NCT05254743 2026-04-01
BRUIN-CLL-314
Eli Lilly and Company
Phase 3 Recruiting
Clinical Trials
9 trialsNCT03970096 2026-03-12
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT05865301 2026-02-09
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
Stanford University
Recruiting
NCT03670966 2025-10-16
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06516679 2025-07-03
Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
Yonsei University
Phase 2 Recruiting
NCT03219450 2025-05-22
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06462248 2024-06-17
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
Prince of Wales Hospital, Shatin, Hong Kong
Phase 2 Recruiting
NCT06111625 2023-11-01
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
Sichuan University
Phase 2 Recruiting
NCT02670564 2019-04-16
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)
Swiss Pediatric Oncology Group
Phase 4 Recruiting